Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

Giorgia Zadra, Caroline F. Ribeiro, Paolo Chetta, Yeung Ho, Stefano Cacciatore, Xueliang Gao, Sudeepa Syamala, Clyde Bango, Cornelia Photopoulos, Ying Huang, Svitlana Tyekucheva, Debora C. Bastos, Jeremy Tchaicha, Brian Lawney, Takuma Uo, Laura D’Anello, Alfredo Csibi, Radha Kalekar, Benjamin Larimer, Leigh EllisLisa M. Butler, Colm Morrissey, Karen McGovern, Vito J. Palombella, Jeffery L. Kutok, Umar Mahmood, Silvano Bosari, Julian Adams, Stephane Peluso, Scott M. Dehm, Stephen R. Plymate, Massimo Loda

Research output: Contribution to journalArticle

Abstract

A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/ AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.

Original languageEnglish
Pages (from-to)631-640
Number of pages10
JournalProceedings of the National Academy of Sciences of the United States of America
Volume116
Issue number2
DOIs
Publication statusPublished - Jan 8 2019

Fingerprint

Lipogenesis
Castration
Androgen Receptors
Prostatic Neoplasms
Fatty Acid Synthases
Neoplasm Metastasis
Organoids
Endoplasmic Reticulum Stress
Growth
Lipid Metabolism
Heterografts
Proteins
Fatty Acids

Keywords

  • Androgen signaling
  • AR-V7
  • Fatty acid synthase
  • Metabolomics
  • Metastatic prostate cancer

ASJC Scopus subject areas

  • General

Cite this

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. / Zadra, Giorgia; Ribeiro, Caroline F.; Chetta, Paolo; Ho, Yeung; Cacciatore, Stefano; Gao, Xueliang; Syamala, Sudeepa; Bango, Clyde; Photopoulos, Cornelia; Huang, Ying; Tyekucheva, Svitlana; Bastos, Debora C.; Tchaicha, Jeremy; Lawney, Brian; Uo, Takuma; D’Anello, Laura; Csibi, Alfredo; Kalekar, Radha; Larimer, Benjamin; Ellis, Leigh; Butler, Lisa M.; Morrissey, Colm; McGovern, Karen; Palombella, Vito J.; Kutok, Jeffery L.; Mahmood, Umar; Bosari, Silvano; Adams, Julian; Peluso, Stephane; Dehm, Scott M.; Plymate, Stephen R.; Loda, Massimo.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 116, No. 2, 08.01.2019, p. 631-640.

Research output: Contribution to journalArticle

Zadra, G, Ribeiro, CF, Chetta, P, Ho, Y, Cacciatore, S, Gao, X, Syamala, S, Bango, C, Photopoulos, C, Huang, Y, Tyekucheva, S, Bastos, DC, Tchaicha, J, Lawney, B, Uo, T, D’Anello, L, Csibi, A, Kalekar, R, Larimer, B, Ellis, L, Butler, LM, Morrissey, C, McGovern, K, Palombella, VJ, Kutok, JL, Mahmood, U, Bosari, S, Adams, J, Peluso, S, Dehm, SM, Plymate, SR & Loda, M 2019, 'Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer', Proceedings of the National Academy of Sciences of the United States of America, vol. 116, no. 2, pp. 631-640. https://doi.org/10.1073/pnas.1808834116
Zadra, Giorgia ; Ribeiro, Caroline F. ; Chetta, Paolo ; Ho, Yeung ; Cacciatore, Stefano ; Gao, Xueliang ; Syamala, Sudeepa ; Bango, Clyde ; Photopoulos, Cornelia ; Huang, Ying ; Tyekucheva, Svitlana ; Bastos, Debora C. ; Tchaicha, Jeremy ; Lawney, Brian ; Uo, Takuma ; D’Anello, Laura ; Csibi, Alfredo ; Kalekar, Radha ; Larimer, Benjamin ; Ellis, Leigh ; Butler, Lisa M. ; Morrissey, Colm ; McGovern, Karen ; Palombella, Vito J. ; Kutok, Jeffery L. ; Mahmood, Umar ; Bosari, Silvano ; Adams, Julian ; Peluso, Stephane ; Dehm, Scott M. ; Plymate, Stephen R. ; Loda, Massimo. / Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer. In: Proceedings of the National Academy of Sciences of the United States of America. 2019 ; Vol. 116, No. 2. pp. 631-640.
@article{c69f7d6aa2d9421980a73db7b6ef37b5,
title = "Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer",
abstract = "A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87{\%} of metastases. AR-V7 was found in 39{\%} of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/ AR-V7 double-positive metastases were found in 77{\%} of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.",
keywords = "Androgen signaling, AR-V7, Fatty acid synthase, Metabolomics, Metastatic prostate cancer",
author = "Giorgia Zadra and Ribeiro, {Caroline F.} and Paolo Chetta and Yeung Ho and Stefano Cacciatore and Xueliang Gao and Sudeepa Syamala and Clyde Bango and Cornelia Photopoulos and Ying Huang and Svitlana Tyekucheva and Bastos, {Debora C.} and Jeremy Tchaicha and Brian Lawney and Takuma Uo and Laura D’Anello and Alfredo Csibi and Radha Kalekar and Benjamin Larimer and Leigh Ellis and Butler, {Lisa M.} and Colm Morrissey and Karen McGovern and Palombella, {Vito J.} and Kutok, {Jeffery L.} and Umar Mahmood and Silvano Bosari and Julian Adams and Stephane Peluso and Dehm, {Scott M.} and Plymate, {Stephen R.} and Massimo Loda",
year = "2019",
month = "1",
day = "8",
doi = "10.1073/pnas.1808834116",
language = "English",
volume = "116",
pages = "631--640",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "2",

}

TY - JOUR

T1 - Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer

AU - Zadra, Giorgia

AU - Ribeiro, Caroline F.

AU - Chetta, Paolo

AU - Ho, Yeung

AU - Cacciatore, Stefano

AU - Gao, Xueliang

AU - Syamala, Sudeepa

AU - Bango, Clyde

AU - Photopoulos, Cornelia

AU - Huang, Ying

AU - Tyekucheva, Svitlana

AU - Bastos, Debora C.

AU - Tchaicha, Jeremy

AU - Lawney, Brian

AU - Uo, Takuma

AU - D’Anello, Laura

AU - Csibi, Alfredo

AU - Kalekar, Radha

AU - Larimer, Benjamin

AU - Ellis, Leigh

AU - Butler, Lisa M.

AU - Morrissey, Colm

AU - McGovern, Karen

AU - Palombella, Vito J.

AU - Kutok, Jeffery L.

AU - Mahmood, Umar

AU - Bosari, Silvano

AU - Adams, Julian

AU - Peluso, Stephane

AU - Dehm, Scott M.

AU - Plymate, Stephen R.

AU - Loda, Massimo

PY - 2019/1/8

Y1 - 2019/1/8

N2 - A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/ AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.

AB - A hallmark of prostate cancer progression is dysregulation of lipid metabolism via overexpression of fatty acid synthase (FASN), a key enzyme in de novo fatty acid synthesis. Metastatic castration-resistant prostate cancer (mCRPC) develops resistance to inhibitors of androgen receptor (AR) signaling through a variety of mechanisms, including the emergence of the constitutively active AR variant V7 (AR-V7). Here, we developed an FASN inhibitor (IPI-9119) and demonstrated that selective FASN inhibition antagonizes CRPC growth through metabolic reprogramming and results in reduced protein expression and transcriptional activity of both full-length AR (AR-FL) and AR-V7. Activation of the reticulum endoplasmic stress response resulting in reduced protein synthesis was involved in IPI-9119–mediated inhibition of the AR pathway. In vivo, IPI-9119 reduced growth of AR-V7–driven CRPC xenografts and human mCRPC-derived organoids and enhanced the efficacy of enzalutamide in CRPC cells. In human mCRPC, both FASN and AR-FL were detected in 87% of metastases. AR-V7 was found in 39% of bone metastases and consistently coexpressed with FASN. In patients treated with enzalutamide and/or abiraterone FASN/ AR-V7 double-positive metastases were found in 77% of cases. These findings provide a compelling rationale for the use of FASN inhibitors in mCRPCs, including those overexpressing AR-V7.

KW - Androgen signaling

KW - AR-V7

KW - Fatty acid synthase

KW - Metabolomics

KW - Metastatic prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85059607804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059607804&partnerID=8YFLogxK

U2 - 10.1073/pnas.1808834116

DO - 10.1073/pnas.1808834116

M3 - Article

C2 - 30578319

AN - SCOPUS:85059607804

VL - 116

SP - 631

EP - 640

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 2

ER -